Attached files
| file | filename |
|---|---|
| EX-3.1 - EXHIBIT 3.1 - Shire plc | dp46069_ex0301.htm |
| 8-K - FORM 8-K - Shire plc | dp46069_8k.htm |
Exhibit 99.1
|
Press Release
www.shire.com
|
 |
Results of the 2014 Annual General Meeting
April 29, 2014 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that at its Annual General Meeting held at The Merrion Hotel, Upper Merrion Street, Dublin 2, Ireland at 1.30 pm today, all resolutions contained in the notice of meeting were decided by poll vote. The results of the poll are as follows:
|
Resolution
|
For (including discretionary votes)
|
%
|
Against
|
%
|
Votes cast as a % of relevant shares in issue
|
Withheld
|
|
Ordinary Resolutions
|
||||||
|
1. To receive the Company’s Annual Report and Accounts for the year ended December 31, 2013.
|
400,965,756
|
98.95%
|
4,249,303
|
1.05%
|
68.80%
|
1,472,435
|
|
2. To approve the Directors’ Remuneration Report.
|
391,218,791
|
96.97%
|
12,224,728
|
3.03%
|
68.50%
|
3,243,975
|
|
3. To approve the Directors’ Remuneration Policy.
|
374,694,890
|
94.71%
|
20,926,142
|
5.29%
|
67.17%
|
11,066,462
|
|
4. To elect Dominic Blakemore as a Director.
|
404,467,447
|
99.82%
|
716,284
|
0.18%
|
68.80%
|
1,503,763
|
|
5. To re-elect William Burns as a Director.
|
400,680,783
|
98.89%
|
4,510,166
|
1.11%
|
68.80%
|
1,496,545
|
|
6. To re-elect Dr. Steven Gillis as a Director.
|
404,565,517
|
99.84%
|
628,936
|
0.16%
|
68.80%
|
1,493,041
|
|
7. To re-elect Dr. David Ginsburg as a Director.
|
404,559,335
|
99.84%
|
630,570
|
0.16%
|
68.80%
|
1,497,589
|
|
8. To re-elect David Kappler as a Director.
|
398,241,506
|
98.74%
|
5,089,868
|
1.26%
|
68.48%
|
3,356,120
|
|
9. To re-elect Susan Kilsby as a Director.
|
391,916,029
|
96.72%
|
13,277,757
|
3.28%
|
68.80%
|
1,493,708
|
|
10. To re-elect Anne Minto as a Director.
|
400,967,152
|
99.45%
|
2,206,094
|
0.55%
|
68.45%
|
3,514,248
|
|
11. To re-elect Dr. Flemming Ornskov as a Director.
|
404,554,602
|
99.84%
|
632,552
|
0.16%
|
68.80%
|
1,500,340
|
|
12. To elect David Stout as a Director.
|
403,130,381
|
99.49%
|
2,060,469
|
0.51%
|
68.80%
|
1,496,644
|
|
13. To re-appoint Deloitte LLP as the Company’s Auditor.
|
401,119,071
|
98.99%
|
4,096,849
|
1.01%
|
68.80%
|
1,471,574
|
|
14. To authorize the Audit, Compliance & Risk Committee to determine the remuneration of the Auditor.
|
402,286,337
|
99.93%
|
284,166
|
0.07%
|
68.35%
|
4,116,991
|
|
15. To approve the increase in the Company’s borrowing powers.
|
404,516,894
|
99.86%
|
553,107
|
0.14%
|
68.78%
|
1,617,493
|
|
16. To authorize the allotment of shares.
|
373,096,915
|
92.54%
|
30,095,078
|
7.46%
|
68.46%
|
3,495,501
|
|
Special Resolutions
|
||||||
|
17. To authorize the disapplication of pre-emption rights.
|
397,955,909
|
98.47%
|
6,202,843
|
1.53%
|
68.62%
|
2,528,742
|
|
18. To authorize market purchases.
|
404,995,809
|
99.95%
|
195,629
|
0.05%
|
68.80%
|
1,496,056
|
|
19. To approve the notice period for general meetings.
|
342,512,195
|
84.53%
|
62,696,077
|
15.47%
|
68.80%
|
1,479,222
|
As at the record date, April 27, 2014, there were 588,965,802 ordinary shares in issue (excluding shares held in treasury). Shareholders are entitled to one vote per share. A vote “withheld” is not a vote in law and is not counted in the calculation of the proportion of votes validly cast.
In accordance with Listing Rule 9.6.2R copies of the relevant resolutions passed at the meeting have been submitted to the National Storage Mechanism and will be available for viewing shortly at: www.morningstar.co.uk/uk/nsm.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
|
Investor Relations
|
||
|
Jeff Poulton
|
jpoulton@shire.com
|
+1 781 482 0945
|
|
Eric Rojas
|
erojas@shire.com
|
+1 781 482 0999
|
|
Sarah Elton-Farr
|
seltonfarr@shire.com
|
+44 1256 894157
|
|
Media
|
||
|
Jessica Mann
|
jmann@shire.com
|
+44 1256 894 280
|
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.
www.shire.com